FDA (2003) Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products—general considerations. Food and Drug Administration, Rockville

Google Scholar 

Morais JAG, Lobato MdR (2010) The new European Medicines Agency guideline on the investigation of bioequivalence. Basic Clin Pharmacol Toxicol 106(3):221–225. https://doi.org/10.1111/j.1742-7843.2009.00518.x

Article  PubMed  CAS  Google Scholar 

Jalali RK, Rasaily D (2018) Generic drug and bioequivalence studies. In: Pharmaceutical medicine and translational clinical researched. Elsevier, pp327–339. https://doi.org/10.1016/B978-0-12-802103-3.00021-3

Bego M, Patel N, Cristofoletti R, Rostami-Hodjegan A (2022) Proof of concept in assignment of within-subject variability during virtual bioequivalence studies: propagation of intra-subject variation in gastrointestinal physiology using physiologically based pharmacokinetic modeling. AAPS J 24(1):21. https://doi.org/10.1208/s12248-021-00672-z

Article  PubMed  Google Scholar 

Han M, He Y, Liang J, Yao F, Lu P, Yan H, Wang J, Xie Y, Li X, Liu Q (2024) Pharmacokinetics and bioequivalence study of candesartan cilexetil tablet in Chinese volunteers under fasting condition: an open-label, randomized-sequence, 2-period crossover study. Transl Clin Pharmacol 32(2):107. https://doi.org/10.12793/tcp.2024.32.e10

Article  PubMed  PubMed Central  Google Scholar 

Lee S-M, Jang J-H, Jeong S-H (2024) Exploring gender differences in pharmacokinetics of central nervous system related medicines based on a systematic review approach. Naunyn Schmiedebergs Arch Pharmacol 397:8311–8347. https://doi.org/10.1007/s00210-024-03190-9

Article  PubMed  CAS  Google Scholar 

Jeong S-H, Jang J-H, Cho H-Y, Lee Y-B (2024) Sex differences in 4-tert-octylphenol toxicokinetics: Exploration of sex as an effective covariate through an in vivo modeling approach. Toxicology 502:153733. https://doi.org/10.1016/j.tox.2024.153733

Article  PubMed  CAS  Google Scholar 

Karalis V, Symillides M, Macheras P (2012) Bioequivalence of highly variable drugs: a comparison of the newly proposed regulatory approaches by FDA and EMA. Pharm Res 29:1066–1077. https://doi.org/10.1007/s11095-011-0651-y

Article  PubMed  CAS  Google Scholar 

Karalis V, Macheras P, Van Peer A, Shah VP (2008) Bioavailability and bioequivalence: focus on physiological factors and variability. Pharm Res 25:1956–1962. https://doi.org/10.1007/s11095-008-9645-9

Article  PubMed  CAS  Google Scholar 

Ibarra M, Vázquez M, Fagiolino P (2017) Sex effect on average bioequivalence. Clin Ther 39(1):23–33. https://doi.org/10.1016/j.clinthera.2016.11.024

Article  PubMed  CAS  Google Scholar 

Almeda S, Filipe A, Almeida A, Wong H, Caparrós N, Tanguay M (2005) Comparative bioavailability of two formulations of levofloxacin and effect of sex on bioequivalence analysis. Arzneim Forsch Drug Res 55(7):414–419. https://doi.org/10.1055/s-0031-1296880

Article  Google Scholar 

Almeida S, Filipe A, Almeida A, Gich I, Antonijoan R, Puntes M, Barbanoj M, Caturla MC (2006) Comparative study on the bioequivalence of two formulations of pravastatin. Arzneim Forsch Drug Res 56(2):70–75. https://doi.org/10.1055/s-0031-1296704

Article  CAS  Google Scholar 

Chen M-L, Williams RL (1995) Women in bioavailability/bioequivalence trials—A regulatory perspective. Drug Inf J 29(3):813–820. https://doi.org/10.1177/009286159502900304

Article  Google Scholar 

Chen ML, Lee SC, Ng MJ, Schuirmann DJ, Lesko LJ, Williams RL (2000) Pharmacokinetic analysis of bioequivalence trials: Implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin Pharmacol Ther 68(5):510–521. https://doi.org/10.1067/mcp.2000.111184

Article  PubMed  CAS  Google Scholar 

Fagiolino P, González N, Vázquez M, Eiraldi R (2007) Itraconazole bioequivalence revisited: Influence of gender on highly variable drugs. Open Drug Metab J 1:7–13. https://doi.org/10.2174/1874073100701010007

Article  CAS  Google Scholar 

Gundeti M, Murthy A, Jamdade S, Ahmed T (2024) Evaluating gender effect in the generic bioequivalence studies by physiologically based pharmacokinetic modeling–A case study of dextromethorphan modified release tablets. Biopharm Drug Dispos. https://doi.org/10.1002/bdd.2389

Article  PubMed  Google Scholar 

Ibarra M, Magallanes L, Lorier M, Vázquez M, Fagiolino P (2016) Sex-by-formulation interaction assessed through a bioequivalence study of efavirenz tablets. Eur J Pharm Sci 85:106–111. https://doi.org/10.1016/j.ejps.2016.02.001

Article  PubMed  CAS  Google Scholar 

Koren G, Nordeng H, MacLeod S (2013) Gender differences in drug bioequivalence: time to rethink practices. Clin Pharmacol Ther 93(3):260–262. https://doi.org/10.1038/clpt.2012.233

Article  PubMed  CAS  Google Scholar 

Romodanovsky D, Goryachev D, Khokhlov A, Miroshnikov A (2018) Influence of sex differences on pharmacokinetics of drugs within the framework of bioequivalence studies of generic medicinal products. Acta Biomed Sci 3(5):94–105. https://doi.org/10.29413/ABS.2018-3.5.15

Article  Google Scholar 

Chen M-L, Shah V, Patnaik R, Adams W, Hussain A, Conner D, Mehta M, Malinowski H, Lazor J, Huang S-M (2001) Bioavailability and bioequivalence: an FDA regulatory overview. Pharm Res 18:1645–1650. https://doi.org/10.1023/A:1013319408893

Article  PubMed  CAS  Google Scholar 

Chow SC (2014) Bioavailability and bioequivalence in drug development. Wiley Interdiscip Rev Comput Stat 6(4):304–312. https://doi.org/10.1002/wics.1310

Article  PubMed  PubMed Central  Google Scholar 

EMA (2017) Reflection paper on the dissolution specification for generic solid oral immediate release products with systemic action (EMA/CHMP/CVMP/QWP/336031/2017). European Medicines Agency (EMA), London, UK

FDA (2018) Waiver of in vivo bioavailability and bioequivalence studies for immediaterelease solid oral dosage forms base on a Biopharmaceutics Classification System. Maryland, EUA, 2017:19

Jeong S-H, Jang J-H, Lee Y-B (2023) Exploring differences in pharmacometrics of rabeprazole between genders via population pharmacokinetic-pharmacodynamic modeling. Biomedicines 11(11):3021. https://doi.org/10.3390/biomedicines11113021

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jeong S-H, Jang J-H, Lee Y-B (2024) Is gender an important factor in the precision medicine approach to levocetirizine? Pharmaceutics 16(1):146. https://doi.org/10.3390/pharmaceutics16010146

Article  PubMed  PubMed Central  CAS  Google Scholar 

Tothfalusi L, Endrenyi L, Arieta AG (2009) Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence. Clin Pharmacokinet 48:725–743. https://doi.org/10.2165/11318040-000000000-00000

Article  PubMed  CAS  Google Scholar 

Ring A, Lang B, Kazaroho C, Labes D, Schall R, Schütz H (2019) Sample size determination in bioequivalence studies using statistical assurance. Br J Clin Pharmacol 85(10):2369–2377. https://doi.org/10.1111/bcp.14055

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pabst G, Jaeger H (1990) Review of methods and criteria for the evaluation of bioequivalence studies. Eur J Clin Pharmacol 38:5–10. https://doi.org/10.1007/BF00314794

Article  PubMed  CAS  Google Scholar 

Munoz J, Alcaide D, Ocaña J (2016) Consumer’s risk in the EMA and FDA regulatory approaches for bioequivalence in highly variable drugs. Stat Med 35(12):1933–1943. https://doi.org/10.1002/sim.6834

Article  PubMed  Google Scholar 

Dubois A, Lavielle M, Gsteiger S, Pigeolet E, Mentré F (2011) Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm. Stat Med 30(21):2582–2600. https://doi.org/10.1002/sim.4286

Article  PubMed  Google Scholar 

Singh GJP, Adams WP, Lesko LJ, Shah VP, Molzon JA, Williams RL, Pershing LK (1999) Development of in vivo bioequivalence methodology for dermatologic corticosteroids based on pharmacodynamic modeling. Clin Pharmacol Ther 66(4):346–357. https://doi.org/10.1053/cp.1999.v66.a101209

Article  PubMed  CAS  Google Scholar